

Angela Buonadonna

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3319799/publications.pdf>

Version: 2024-02-01

160
papers

7,749
citations

94381

37
h-index

53190

85
g-index

167
all docs

167
docs citations

167
times ranked

8941
citing authors

#	ARTICLE	IF	CITATIONS
1	Neoadjuvant chemotherapy in high-risk soft tissue sarcomas: A Sarculator-based risk stratification analysis of the ISGâ€”STS 1001 randomized trial. <i>Cancer</i> , 2022, 128, 85-93.	2.0	46
2	Prognostic and Predictive Role of Body Mass Index (BMI) in Metastatic Colorectal Cancer (mCRC): A Pooled Analysis of Tribe and Tribe-2 Studies by GONO. <i>Clinical Colorectal Cancer</i> , 2022, , .	1.0	3
3	Systemic Treatments for Advanced Small Bowel Adenocarcinoma: A Systematic Review. <i>Cancers</i> , 2022, 14, 1502.	1.7	5
4	Machine Learning Application in a Phase I Clinical Trial Allows for the Identification of Clinicalâ€”Biomolecular Markers Significantly Associated With Toxicity. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 111, 686-696.	2.3	8
5	Treatments after second progression in metastatic colorectal cancer: A pooled analysis of the TRIBE and TRIBE2 studies. <i>European Journal of Cancer</i> , 2022, 170, 64-72.	1.3	3
6	Upfront Modified Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Panitumumab Versus Fluorouracil, Leucovorin, and Oxaliplatin Plus Panitumumab for Patients With <i>RAS/BRAF</i> Wild-Type Metastatic Colorectal Cancer: The Phase III TRIPLETE Study by GONO. <i>Journal of Clinical Oncology</i> , 2022, 40, 2878-2888.	0.8	24
7	Treatments after progression to first-line FOLFOXIRI and bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies by GONO. <i>British Journal of Cancer</i> , 2021, 124, 183-190.	2.9	7
8	Feasibility and Oncological Outcome of Preoperative Chemoradiation With IMRT Dose Intensification for Locally Advanced Esophageal and Gastroesophageal Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 626275.	1.3	4
9	Trabectedin for Patients with Advanced Soft Tissue Sarcoma: A Non-Interventional, Retrospective, Multicenter Study of the Italian Sarcoma Group. <i>Cancers</i> , 2021, 13, 1053.	1.7	15
10	Ventricular Arrhythmias Due to Glomangiosarcoma Cardiac Metastases. <i>JACC: CardioOncology</i> , 2021, 3, 150-153.	1.7	2
11	IL15RA and SMAD3 Genetic Variants Predict Overall Survival in Metastatic Colorectal Cancer Patients Treated with FOLFIRI Therapy: A New Paradigm. <i>Cancers</i> , 2021, 13, 1705.	1.7	10
12	CEA increase as a marker of disease progression after first-line induction therapy in metastatic colorectal cancer patients. A pooled analysis of TRIBE and TRIBE2 studies. <i>British Journal of Cancer</i> , 2021, 125, 839-845.	2.9	9
13	Drug Holidays and Overall Survival of Patients with Metastatic Colorectal Cancer. <i>Cancers</i> , 2021, 13, 3504.	1.7	5
14	Oligometastatic colorectal cancer: prognosis, role of locoregional treatments and impact of first-line chemotherapyâ€”a pooled analysis of TRIBE and TRIBE2 studies by Gruppo Oncologico del Nord Ovest. <i>European Journal of Cancer</i> , 2020, 139, 81-89.	1.3	17
15	A Novel Kindred with Familial Gastrointestinal Stromal Tumors Caused by a Rare KIT Germline Mutation (N655K): Clinico-Pathological Presentation and TKI Sensitivity. <i>Journal of Personalized Medicine</i> , 2020, 10, 234.	1.1	13
16	Determinants of choice in offering drug holidays during first-line therapy for metastatic colorectal cancer. <i>Future Oncology</i> , 2020, 16, 2645-2660.	1.1	1
17	Integration of Serum Metabolomics into Clinical Assessment to Improve Outcome Prediction of Metastatic Soft Tissue Sarcoma Patients Treated with Trabectedin. <i>Cancers</i> , 2020, 12, 1983.	1.7	15
18	Immunogenetic markers in IL17F predict the risk of metastases spread and overall survival in rectal cancer patients treated with neoadjuvant chemoradiotherapy. <i>Radiotherapy and Oncology</i> , 2020, 149, 30-37.	0.3	6

#	ARTICLE	IF	CITATIONS
19	Fluoropyrimidine-Associated Cardiotoxicity: Probably Not So Rare As It Seems. <i>Oncologist</i> , 2020, 25, e1254-e1254.	1.9	8
20	Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial. <i>Lancet Oncology</i> , The, 2020, 21, 497-507.	5.1	196
21	The MIMIC Study: Prognostic Role and Cutoff Definition of Monocyte-to-Lymphocyte Ratio and Lactate Dehydrogenase Levels in Metastatic Colorectal Cancer. <i>Oncologist</i> , 2020, 25, 661-668.	1.9	21
22	Clonal Selection of a Novel Deleterious TP53 Somatic Mutation Discovered in ctDNA of a KIT/PDGFR α Wild-Type Gastrointestinal Stromal Tumor Resistant to Imatinib. <i>Frontiers in Pharmacology</i> , 2020, 11, 36.	1.6	10
23	Khorana score and thromboembolic risk in stage II-III colorectal cancer patients: a <i>post hoc</i> analysis from the adjuvant TOSCA trial. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883591989985.	1.4	6
24	P.05.34 EVALUATION OF NEOANGIOGENESIS IN LOCALLY ADVANCED GASTRIC CANCER BEFORE AND AFTER NEOADJUVANT RADIOCHEMOTHERAPY BY PROBE CONFOCAL LASER ENDOMICROSCOPY (PCLE). <i>Digestive and Liver Disease</i> , 2019, 51, e198.	0.4	0
25	<p>Probe-based confocal laser endomicroscopy (pCLE) is a suitable method for extrapulmonary high grade neuroendocrine rectal carcinoma (HGNEC) evaluation</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 4577-4583.	1.0	0
26	The role of sidedness in second-line therapy for RAS wild-type colorectal cancer: a network meta-analysis (NMA). <i>Annals of Oncology</i> , 2019, 30, iv79.	0.6	0
27	Evaluation of neoangiogenesis in locally advanced gastric cancer before and after neoadjuvant radiochemotherapy by probe confocal laser endomicroscopy (PCLE). <i>Annals of Oncology</i> , 2019, 30, iv80-iv81.	0.6	1
28	Prognostic and predictive role of body mass index (BMI) in metastatic colorectal cancer (mCRC): A pooled analysis of TRIBE and TRIBE-2 studies by GONO. <i>Annals of Oncology</i> , 2019, 30, v218-v219.	0.6	0
29	Combination of germline variations associated with survival of folinic acid, fluorouracil and irinotecan-treated metastatic colorectal cancer patients. <i>Pharmacogenomics</i> , 2019, 20, 1179-1187.	0.6	6
30	PO-0821 Long-term outcome of an organ preservation strategy following chemoradiotherapy in rectal cancer. <i>Radiotherapy and Oncology</i> , 2019, 133, S429-S430.	0.3	0
31	EP-1607 Preoperative Radiation Therapy and IORT in Retroperitoneal Soft Tissue Sarcomas. Long Term Outcome. <i>Radiotherapy and Oncology</i> , 2019, 133, S866.	0.3	0
32	Germline variability and tumor expression level of ribosomal protein gene RPL28 are associated with survival of metastatic colorectal cancer patients. <i>Scientific Reports</i> , 2019, 9, 13008.	1.6	23
33	Diagnostic, Prognostic, Predictive and Therapeutic Tissue Biomarkers in Gastric Cancer. <i>Current Clinical Pathology</i> , 2019, , 83-106.	0.0	0
34	Role of Bruton's Tyrosine Kinase in Stage III Colorectal Cancer. <i>Cancers</i> , 2019, 11, 880.	1.7	11
35	New Agents in the Treatment of Advanced Gastric Cancer: Targeted Therapy and Immunotherapy. <i>Current Clinical Pathology</i> , 2019, , 121-132.	0.0	0
36	Combined Modality Treatment for Locally Advanced Gastric Cancer: Current Evidences and New Perspectives. <i>Current Clinical Pathology</i> , 2019, , 133-145.	0.0	0

#	ARTICLE	IF	CITATIONS
37	Surgical Strategies in Gastric Cancer. <i>Current Clinical Pathology</i> , 2019, , 147-152.	0.0	0
38	RPL28 Promoter polymorphism RS4806668 is associated with reduced survival in folfiri-treated metastatic colorectal cancer patients. <i>Drug Metabolism and Pharmacokinetics</i> , 2019, 34, S64-S65.	1.1	0
39	Clinical Significance of Polymorphisms in Immune Response Genes in Hepatitis C-Related Hepatocellular Carcinoma. <i>Frontiers in Microbiology</i> , 2019, 10, 475.	1.5	11
40	The INTERACT Trial: Long-term results of a randomised trial on preoperative capecitabine-based radiochemotherapy intensified by concomitant boost or oxaliplatin, for cT2 (distal)â€“cT3 rectal cancer. <i>Radiotherapy and Oncology</i> , 2019, 134, 110-118.	0.3	48
41	Impact of Metformin Use and Diabetic Status During Adjuvant Fluoropyrimidine-Oxaliplatin Chemotherapy on the Outcome of Patients with Resected Colon Cancer: A TOSCA Study Subanalysis. <i>Oncologist</i> , 2019, 24, 385-393.	1.9	23
42	Development and validation of LC-MS/MS method for imatinib and norimatinib monitoring by finger-prick DBS in gastrointestinal stromal tumor patients. <i>PLoS ONE</i> , 2019, 14, e0225225.	1.1	21
43	Germline Polymorphisms in the Nuclear Receptors PXR and VDR as Novel Prognostic Markers in Metastatic Colorectal Cancer Patients Treated With FOLFIRI. <i>Frontiers in Oncology</i> , 2019, 9, 1312.	1.3	14
44	Multidisciplinary treatment approach for primary thyroid spindle cell sarcoma: A case report. <i>Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique</i> , 2019, 23, 46-49.	0.6	0
45	Systematic vs. on-demand early palliative care in gastric cancer patients: a randomized clinical trial assessing patient and healthcare service outcomes. <i>Supportive Care in Cancer</i> , 2019, 27, 2425-2434.	1.0	34
46	The Genotype for <i><sc>DPYD</sc></i> Risk Variants in Patients With Colorectal Cancer and the Related Toxicity Management Costs in Clinical Practice. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 994-1002.	2.3	39
47	Neoadjuvant epirubicyn, oxaliplatin, capecitabine and radiation therapy (NEOX-RT) followed by surgery for locally advanced gastric cancer (LAGC): A phase II multicentric study.. <i>Journal of Clinical Oncology</i> , 2019, 37, 4066-4066.	0.8	2
48	Impact of gender on the safety profile of chemotherapy plus bevacizumab in mCRC: A pooled analysis of TRIBE and TRIBE2 studies.. <i>Journal of Clinical Oncology</i> , 2019, 37, 3534-3534.	0.8	0
49	Impact of age on safety and efficacy of first-line FOLFOXIRI/bevacizumab in mCRC: A pooled analysis of TRIBE and TRIBE2 studies.. <i>Journal of Clinical Oncology</i> , 2019, 37, 3536-3536.	0.8	0
50	The predictive and prognostic potential of plasma telomerase reverse transcriptase (TERT) RNA in rectal cancer patients. <i>British Journal of Cancer</i> , 2018, 118, 878-886.	2.9	20
51	Primary tumor sidedness and benefit from FOLFOXIRI plus bevacizumab as initial therapy for metastatic colorectal cancer. Retrospective analysis of the TRIBE trial by GONO. <i>Annals of Oncology</i> , 2018, 29, 1528-1534.	0.6	83
52	Prognostic and predictive role of neutrophil/lymphocytes ratio in metastatic colorectal cancer: a retrospective analysis of the TRIBE study by GONO. <i>Annals of Oncology</i> , 2018, 29, 924-930.	0.6	99
53	A new mutation of the CDH1 gene in a patient with an aggressive signet-ring cell carcinoma of the stomach. <i>Cancer Biology and Therapy</i> , 2018, 19, 254-259.	1.5	9
54	Determinants of oncologistâ€™s choice in offering drug holidays during first line therapy for patients with metastatic colorectal cancer. <i>Annals of Oncology</i> , 2018, 29, viii197-viii198.	0.6	0

#	ARTICLE	IF	CITATIONS
55	Development of a new clinical nomogram including velocity rate of disease progression to predict outcome in metastatic colorectal cancer patients treated with bevacizumab beyond progression: A subanalysis from tribe trial. <i>Annals of Oncology</i> , 2018, 29, v67.	0.6	0
56	CAPTEM or FOLFIRI as second-line therapy in neuroendocrine carcinomas and exploratory analysis of predictive role of PET imaging and biological markers (SENECA study). <i>Annals of Oncology</i> , 2018, 29, viii477-viii478.	0.6	0
57	Bone sarcomas: ESMOâ€™PaedCanâ€™EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2018, 29, iv79-iv95.	0.6	380
58	A Clinical-Genetic Score to Identify Surgically Resected Colorectal Cancer Patients Benefiting From an Adjuvant Fluoropyrimidine-Based Therapy. <i>Frontiers in Pharmacology</i> , 2018, 9, 1101.	1.6	8
59	Gastrointestinal stromal tumours: ESMOâ€™EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2018, 29, iv68-iv78.	0.6	413
60	Soft tissue and visceral sarcomas: ESMOâ€™EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2018, 29, iv51-iv67.	0.6	641
61	Association of STAT-3 rs1053004 and VDR rs11574077 With FOLFIRI-Related Gastrointestinal Toxicity in Metastatic Colorectal Cancer Patients. <i>Frontiers in Pharmacology</i> , 2018, 9, 367.	1.6	24
62	A phase II randomised (calibrated design) study on the activity of the single-agent trabectedin in metastatic or locally relapsed uterine leiomyosarcoma. <i>British Journal of Cancer</i> , 2018, 119, 565-571.	2.9	15
63	Characterizing Metastatic HER2-Positive Gastric Cancer at the CDH1 Haplotype. <i>International Journal of Molecular Sciences</i> , 2018, 19, 47.	1.8	17
64	<i>DPYD</i> and <i>UGT1A1</i> genotyping to predict adverse events during first-line FOLFIRI or FOLFOXIRI plus bevacizumab in metastatic colorectal cancer. <i>Oncotarget</i> , 2018, 9, 7859-7866.	0.8	25
65	An observational, multicenter, retrospective, Italian Sarcoma Group (ISG) study of trabectedin in patients with advanced soft tissue sarcoma (STS).. <i>Journal of Clinical Oncology</i> , 2018, 36, e23502-e23502.	0.8	0
66	Abstract 3889: <i>RPL28</i> promoter polymorphism rs4806668 is associated with reduced survival in FOLFIRI-treated metastatic colorectal cancer patients. <i>Cancer Research</i> , 2018, 78, 3889-3889.	0.4	1
67	Cost Evaluation of Irinotecanâ€™Related Toxicities Associated With the <i>UGT1A1*28</i> Patient Genotype. <i>Clinical Pharmacology and Therapeutics</i> , 2017, 102, 123-130.	2.3	31
68	Fieldâ€™assisted paper spray mass spectrometry for therapeutic drug monitoring: 1. the case of imatinib in plasma. <i>Journal of Mass Spectrometry</i> , 2017, 52, 283-289.	0.7	4
69	UGT1A polymorphisms as genetic biomarkers for hepatocellular carcinoma risk in Caucasian population. <i>Liver International</i> , 2017, 37, 1345-1353.	1.9	18
70	Long-term Follow-up and Post-relapse Outcome of Patients with Localized Retroperitoneal Sarcoma Treated in the Italian Sarcoma Group-Soft Tissue Sarcoma (ISG-STS) Protocol 0303. <i>Annals of Surgical Oncology</i> , 2017, 24, 3872-3879.	0.7	24
71	A noninterventional, multicenter, prospective phase IV study of trabectedin in patients with advanced soft tissue sarcoma. <i>Anti-Cancer Drugs</i> , 2017, 28, 1157-1165.	0.7	29
72	Probe-based confocal laser endomicroscopy for in vivo evaluation of the tumor vasculature in gastric and rectal carcinomas. <i>Scientific Reports</i> , 2017, 7, 9819.	1.6	22

#	ARTICLE	IF	CITATIONS
73	Genotype-Guided Dosing Study of FOLFIRI plus Bevacizumab in Patients with Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 918-924.	3.2	35
74	Improved Progression-Free Survival in Irinotecan-Treated Metastatic Colorectal Cancer Patients Carrying the HNF1A Coding Variant p.I27L. <i>Frontiers in Pharmacology</i> , 2017, 8, 712.	1.6	22
75	The routine real-life use of trabectedin (T) in patients with advanced soft tissue sarcoma (STS) across Europe: An analysis of overall vs. per country results from Y-IMAGE study. <i>Annals of Oncology</i> , 2017, 28, v529-v530.	0.6	0
76	HLA-G 3'UTR Polymorphisms Predict Drug-Induced G3-4 Toxicity Related to Folinic Acid/5-Fluorouracil/Oxaliplatin (FOLFOX4) Chemotherapy in Non-Metastatic Colorectal Cancer. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1366.	1.8	13
77	Genetic biomarkers for hepatocellular cancer risk in a caucasian population. <i>World Journal of Gastroenterology</i> , 2017, 23, 6674-6684.	1.4	26
78	Confirmed Activity and Tolerability of Weekly Paclitaxel in the Treatment of Advanced Angiosarcoma. <i>Sarcoma</i> , 2016, 2016, 1-7.	0.7	11
79	Pharmacogenetics Biomarkers and Their Specific Role in Neoadjuvant Chemoradiotherapy Treatments: An Exploratory Study on Rectal Cancer Patients. <i>International Journal of Molecular Sciences</i> , 2016, 17, 1482.	1.8	12
80	Angiogenesis evaluation in locally advanced colo-rectal and gastric cancers by probe-based Confocal Laser Endomicroscopy (pCLE). <i>Annals of Oncology</i> , 2016, 27, iv48.	0.6	1
81	Polymorphism of CDH1 Promoter Is a Predictor of Clinical Outcome in Patients with Metastatic Gastric Cancer Treated with chemotherapy. <i>Annals of Oncology</i> , 2016, 27, iv21.	0.6	0
82	Sorafenib in clinical practice: Pooled analysis of two prospective observational studies in hepatocellular carcinoma (HCC). <i>Digestive and Liver Disease</i> , 2016, 48, e45-e46.	0.4	0
83	OC.04.7 IDENTIFICATION OF PROTEOMIC PROFILES ASSOCIATED WITH TUMOR REGRESSION GRADING IN RECTAL CANCER. <i>Digestive and Liver Disease</i> , 2016, 48, e85-e86.	0.4	0
84	P.09.7 PROGNOSTIC SIGNIFICANCE OF CLINICALLY METASTATIC MESORECTAL LYMPH NODES IN LOCALLY ADVANCED RECTAL CANCER TREATED BY NEOADJUVANT CHEMORADIATION: IMPLICATIONS FOR SURGICAL STRATEGIES IN RELATION TO PATHOLOGICAL RESPONSE. <i>Digestive and Liver Disease</i> , 2016, 48, e174.	0.4	0
85	OC.04.2 GENETIC DIVERSITY OF THE KIR/HLA SYSTEM AND OUTCOME OF PATIENTS WITH METASTATIC COLORECTAL CANCER TREATED WITH CHEMOTHERAPY. <i>Digestive and Liver Disease</i> , 2016, 48, e83-e84.	0.4	0
86	Long-Term Outcome of Rectal Cancer With Clinically (EUS/MRI) Metastatic Mesorectal Lymph Nodes Treated by Neoadjuvant Chemoradiation: Role of Organ Preservation Strategies in Relation to Pathologic Response. <i>Annals of Surgical Oncology</i> , 2016, 23, 4302-4309.	0.7	14
87	Association of the germline BRCA2 missense variation Glu2663Lys with high sensitivity to trabectedin-based treatment in soft tissue sarcoma. <i>Cancer Biology and Therapy</i> , 2016, 17, 1017-1021.	1.5	3
88	EP-1406: Cardiac sarcomas: update of an evolving multidisciplinary approach with focus on radiation therapy. <i>Radiotherapy and Oncology</i> , 2016, 119, S655.	0.3	0
89	Morphologic shift associated with aberrant cytokeratin expression in a GIST patient after tyrosine kinase inhibitors therapy. A case report with a brief review of the literature. <i>Pathology Research and Practice</i> , 2016, 212, 63-67.	1.0	9
90	FOLFOXIRI or FOLFIRI plus bevacizumab as first-line treatment of metastatic colorectal cancer: a propensity score-adjusted analysis from two randomized clinical trials. <i>Annals of Oncology</i> , 2016, 27, 843-849.	0.6	46

#	ARTICLE	IF	CITATIONS
91	Predictive role of microRNA-related genetic polymorphisms in the pathological complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer patients. <i>Oncotarget</i> , 2016, 7, 19781-19793.	0.8	14
92	Short, full-dose adjuvant chemotherapy (CT) in high-risk adult soft tissue sarcomas (STS): Long-term follow-up of a randomized clinical trial from the Italian Sarcoma Group and the Spanish Sarcoma Group.. <i>Journal of Clinical Oncology</i> , 2016, 34, 11045-11045.	0.8	0
93	Abstract 1420: IL17F-rs9463772 independently predicts long-term outcome in locally advanced rectal cancer. , 2016, , .		0
94	Hepatocellular Carcinoma In Elderly Patients: final results of The Italian Cohort Of GIDEON (Global) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 <i>Oncology</i> , 2015, 26, vi93.	0.6	1
95	Pre-emptive pharmacogenetic testing implementation for chemotherapy dosage optimization: the translational experience at CRO of Aviano. <i>Annals of Oncology</i> , 2015, 26, vi142.	0.6	0
96	Pharmacokinetic analysis of irinotecan administered in FOLFIRI regimen in combination with bevacizumab from patients enrolled in a genotype-driven phase I study. <i>Annals of Oncology</i> , 2015, 26, vi133.	0.6	0
97	Clinical validity of a <sc><i>DPYD</i></sc>-based pharmacogenetic test to predict severe toxicity to fluoropyrimidines. <i>International Journal of Cancer</i> , 2015, 137, 2971-2980.	2.3	70
98	Final results of the gideon study according to patient etiology: The italian experience. <i>Annals of Oncology</i> , 2015, 26, vi93.	0.6	0
99	A randomized, multicenter, phase II study of vandetanib monotherapy versus vandetanib in combination with gemcitabine versus gemcitabine plus placebo in subjects with advanced biliary tract cancer: the VanGogh study. <i>Annals of Oncology</i> , 2015, 26, 542-547.	0.6	96
100	Malignant cardiac tumors: diagnosis and treatment. <i>Future Cardiology</i> , 2015, 11, 485-500.	0.5	25
101	DPYD c.1905+1G>A and c.2846A>T and UGT1A1*28 allelic variants as predictors of toxicity: Pharmacogenetic translational analysis from the phase III TRIBE study in metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, 3532-3532.	0.8	2
102	FOLFOXIRI plus bevacizumab (bev) versus FOLFIRI plus bev as first-line treatment of metastatic colorectal cancer (mCRC): Updated survival results of the phase III TRIBE trial by the GONO group.. <i>Journal of Clinical Oncology</i> , 2015, 33, 657-657.	0.8	17
103	HLA-G 3'UTR Polymorphisms Impact the Prognosis of Stage II-III CRC Patients in Fluoropyrimidine-Based Treatment. <i>PLoS ONE</i> , 2015, 10, e0144000.	1.1	31
104	Genetic Diversity of the KIR/HLA System and Outcome of Patients with Metastatic Colorectal Cancer Treated with Chemotherapy. <i>PLoS ONE</i> , 2014, 9, e84940.	1.1	40
105	Grade 4 unclassified renal cell carcinoma with sarcomatoid component expressing S-100 protein. A case report with peculiar diagnostic and therapeutic implications. <i>Cancer Biology and Therapy</i> , 2014, 15, 1439-1443.	1.5	7
106	Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer. <i>Annals of Oncology</i> , 2014, 25, 1373-1378.	0.6	84
107	Effort myocardial ischemia during chemotherapy with 5-fluorouracil: an underestimated risk. <i>Annals of Oncology</i> , 2014, 25, 1059-1064.	0.6	67
108	Optimizing Single Agent Panitumumab Therapy in Pre-Treated Advanced Colorectal Cancer. <i>Neoplasia</i> , 2014, 16, 751-756.	2.3	4

#	ARTICLE	IF	CITATIONS
109	Improved outcome with multimodal treatment and imatinib rechallenge in advanced GIST. International Journal of Colorectal Disease, 2014, 29, 639-640.	1.0	5
110	Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer. New England Journal of Medicine, 2014, 371, 1609-1618.	13.9	845
111	Preoperative chemo-radiation therapy for localised retroperitoneal sarcoma: A phase II study from the Italian Sarcoma Group. European Journal of Cancer, 2014, 50, 784-792.	1.3	80
112	A UGT1A1 genotype-guided dosing study of irinotecan in metastatic colorectal cancer (mCRC) patients (pts) treated with FOLFIRI plus bevacizumab (BEV).. Journal of Clinical Oncology, 2014, 32, 562-562.	0.8	0
113	Phase I trial of docetaxel, oxaliplatin, and capecitabine (DOC) in untreated gastric cancer patients. International Journal of Clinical Oncology, 2013, 18, 510-516.	1.0	6
114	Pharmacogenetics of ABC and SLC transporters in metastatic colorectal cancer patients receiving first-line FOLFIRI treatment. Pharmacogenetics and Genomics, 2013, 23, 549-557.	0.7	49
115	FOLFOXIRI plus bevacizumab (bev) versus FOLFIRI plus bev as first-line treatment of metastatic colorectal cancer (MCRC): Results of the phase III randomized TRIBE trial.. Journal of Clinical Oncology, 2013, 31, 336-336.	0.8	25
116	Exocrine and Endocrine Modulation in Common Gastric Carcinoma. American Journal of Clinical Pathology, 2012, 137, 712-721.	0.4	10
117	Neoplastic pericardial disease in lung cancer: Impact on outcomes of different treatment strategies. A multicenter study. Lung Cancer, 2011, 72, 340-347.	0.9	44
118	Preoperative Chemo-radiotherapy For T3 Stage Rectal Cancer Patients: Long-term Outcome Of Multimodality Management And Implications For Risk-adapted Treatment Strategies. International Journal of Radiation Oncology Biology Physics, 2011, 81, S371.	0.4	0
119	Long-Term Outcome of Patients with Complete Pathologic Response after Neoadjuvant Chemoradiation for cT3 Rectal Cancer: Implications for Local Excision Surgical Strategies. Annals of Surgical Oncology, 2011, 18, 3686-3693.	0.7	81
120	Palonosetron in combination with 1-day versus 3-day dexamethasone for prevention of nausea and vomiting following moderately emetogenic chemotherapy: a randomized, multicenter, phase III trial. Supportive Care in Cancer, 2011, 19, 1217-1225.	1.0	96
121	Role of genetic polymorphisms and mutations in colorectal cancer therapy (Review). Molecular Medicine Reports, 2011, 4, 203-8.	1.1	24
122	Genotype-Driven Phase I Study of Irinotecan Administered in Combination With Fluorouracil/Leucovorin in Patients With Metastatic Colorectal Cancer. Journal of Clinical Oncology, 2010, 28, 866-871.	0.8	156
123	FOLFOXIRI plus bevacizumab (BV) versus FOLFIRI plus BV as first-line treatment of metastatic colorectal cancer (MCRC): Preliminary safety results of the phase III randomized TRIBE study by the Gruppo Oncologico Nord-Ovest (GONO).. Journal of Clinical Oncology, 2010, 28, 3543-3543.	0.8	8
124	Evidence-Based Medicine: What does it Mean and Where Are We Going?. , 2010, , 221-241.		0
125	Malignant pericardial effusion: sclerotherapy or local chemotherapy?. British Journal of Cancer, 2009, 101, 734-735.	2.9	16
126	Predictive Role of the UGT1A1, UGT1A7, and UGT1A9 Genetic Variants and Their Haplotypes on the Outcome of Metastatic Colorectal Cancer Patients Treated With Fluorouracil, Leucovorin, and Irinotecan. Journal of Clinical Oncology, 2009, 27, 2457-2465.	0.8	216

#	ARTICLE	IF	CITATIONS
127	PA.122 COMBINATION CHEMOTHERAPY (CT) WITH DOCETAXEL (D), OXALIPLATIN (O), CAPECITABINE (C) IN PATIENTS (PTS) WITH ADVANCED GASTRIC CANCER (AGC): PRELIMINARY RESULTS ON TOXICITY OF A PILOT STUDY. Digestive and Liver Disease, 2008, 40, S119.	0.4	0
128	Effects of a treatment gap during adjuvant chemotherapy in node-positive breast cancer: results of International Breast Cancer Study Group (IBCSG) Trials 13-93 and 14-93. Annals of Oncology, 2007, 18, 1177-1184.	0.6	8
129	Neoadjuvant chemotherapy (CT) and postoperative chemoradiation (PCRT) in locally advanced, resectable, gastric cancer (LAGC). Preliminary results of a pilot study. Journal of Clinical Oncology, 2007, 25, 15078-15078.	0.8	0
130	The Role of UGT1A1*28 Polymorphism in the Pharmacodynamics and Pharmacokinetics of Irinotecan in Patients With Metastatic Colorectal Cancer. Journal of Clinical Oncology, 2006, 24, 3061-3068.	0.8	328
131	Randomized Trial Comparing Axillary Clearance Versus No Axillary Clearance in Older Patients With Breast Cancer: First Results of International Breast Cancer Study Group Trial 10-93. Journal of Clinical Oncology, 2006, 24, 337-344.	0.8	328
132	FOLFOX2 regimen in the treatment of advanced colorectal cancer: a comparison between elderly and young patients. Annals of Oncology, 2006, 17, 1606-1607.	0.6	3
133	Timing of CMF chemotherapy in combination with tamoxifen in postmenopausal women with breast cancer: role of endocrine responsiveness of the tumor. Annals of Oncology, 2005, 16, 716-725.	0.6	18
134	Carboxylesterase Isoform 2 mRNA Expression in Peripheral Blood Mononuclear Cells Is a Predictive Marker of the Irinotecan to SN38 Activation Step in Colorectal Cancer Patients. Clinical Cancer Research, 2005, 11, 6901-6907.	3.2	34
135	A phase II study of capecitabine and weekly docetaxel combination chemotherapy in patients with metastatic breast cancer. Journal of Clinical Oncology, 2005, 23, 804-804.	0.8	1
136	Neoadjuvant Therapy of Rectal Cancer New Treatment Perspectives. Tumori, 2004, 90, 373-378.	0.6	11
137	Toremifene and tamoxifen are equally effective for early-stage breast cancer: first results of International Breast Cancer Study Group Trials 12-93 and 14-93. Annals of Oncology, 2004, 15, 1749-1759.	0.6	90
138	Ifosfamide in the Adjuvant Therapy of Soft Tissue Sarcomas. Oncology, 2003, 65, 80-84.	0.9	173
139	Solid pseudopapillary tumour of the pancreas. Lancet Oncology, The, 2003, 4, 255-256.	5.1	54
140	Somatostatin receptor scintigraphy versus chromogranin A assay in the management of patients with neuroendocrine tumors of different types: clinical role. Annals of Oncology, 2003, 14, 1135-1141.	0.6	67
141	Adjuvant systemic therapies in women with breast cancer: an audit of clinical practice in Italy. Annals of Oncology, 2003, 14, 843-848.	0.6	27
142	Cisplatin may be a Valid Alternative Approach in Ovarian Carcinoma with Carboplatin Hypersensitivity. Report of Three Cases. Tumori, 2003, 89, 311-313.	0.6	12
143	Long-Term Survival in Patients with Metastatic Renal Cell Carcinoma Treated with Continuous Intravenous Infusion of Recombinant Interleukin-2: The Experience of a Single Institution. Tumori, 2003, 89, 400-404.	0.6	6
144	Endocrine Responsiveness and Tailoring Adjuvant Therapy for Postmenopausal Lymph Node-Negative Breast Cancer: A Randomized Trial. Journal of the National Cancer Institute, 2002, 94, 1054-1065.	3.0	138

#	ARTICLE	IF	CITATIONS
145	Prognostic factors in soft tissue sarcomas: a study of 395 patients. <i>European Journal of Surgical Oncology</i> , 2002, 28, 153-164.	0.5	105
146	Metastatic Angiosarcoma of the Spleen. A Case Report and Treatment Approach. <i>Tumori</i> , 2001, 87, 439-443.	0.6	13
147	Adjuvant Chemotherapy for Adult Soft Tissue Sarcomas of the Extremities and Girdles: Results of the Italian Randomized Cooperative Trial. <i>Journal of Clinical Oncology</i> , 2001, 19, 1238-1247.	0.8	631
148	Continuous Infusion Fluorouracil in the Management of Advanced Breast Cancer: A Phase II Study. <i>Tumori</i> , 2000, 86, 42-45.	0.6	10
149	High sensitivity of chromogranin a (CgA) as serum marker of functioning and non-functioning digestive neuroendocrine tumors. <i>Gastroenterology</i> , 2000, 118, A647.	0.6	0
150	Increasing dose of Continuous Infusion Ifosfamide and Fixed dose of Bolus Epirubicin in Soft Tissue Sarcomas. A Study of the Italian Group on Rare Tumors. <i>Tumori</i> , 1999, 85, 229-233.	0.6	13
151	Efficacy of Total Androgen Blockade in Metastatic Prostatic Carcinoma with Transient Hypogonadotropic Hypogonadism: A Case Report. <i>Tumori</i> , 1999, 85, 280-283.	0.6	0
152	Dose-finding study of epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer. <i>Annals of Oncology</i> , 1999, 10, 539-546.	0.6	40
153	Anthracycline dose and liver dysfunction. <i>British Journal of Cancer</i> , 1999, 79, 1943-1943.	2.9	0
154	Prognostic impact of amenorrhoea after adjuvant chemotherapy in premenopausal breast cancer patients with axillary node involvement: results of the international Breast Cancer Study Group (IBCSG) trial VI. <i>European Journal of Cancer</i> , 1998, 34, 632-640.	1.3	206
155	Effectiveness of adjuvant chemotherapy in combination with tamoxifen for node-positive postmenopausal breast cancer patients.. <i>Journal of Clinical Oncology</i> , 1997, 15, 1385-1394.	0.8	114
156	High-Dose Epirubicin in Locally Advanced Operable Noninflammatory Breast Cancer: A Feasibility Trial. <i>Tumori</i> , 1997, 83, 656-660.	0.6	0
157	Duration and reintroduction of adjuvant chemotherapy for node-positive premenopausal breast cancer patients.. <i>Journal of Clinical Oncology</i> , 1996, 14, 1885-1894.	0.8	95
158	Gastric Cancer with Bone Marrow Invasion at Presentation: Case-Report and Review of the Literature. <i>Tumori</i> , 1995, 81, 74-76.	0.6	14
159	Antithrombin III deficiency as a risk factor for catheter-related central vein thrombosis in cancer patients. <i>Thrombosis Research</i> , 1995, 78, 127-137.	0.8	42
160	Epirubicin and ifosfamide in advanced soft tissue sarcomas. <i>Annals of Oncology</i> , 1993, 4, 669-672.	0.6	26